Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan

被引:14
|
作者
Hsu, Ching-Sheng
Liu, Chun-Jen
Lai, Ming-Yang
Chen, Pei-Jer
Kao, Jia-Horng
Chen, Ding-Shinn
机构
[1] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei 100, Taiwan
[2] Buddhist Tzu Chi Gen Hosp, Dept Hepatogastroenterol, Dept Internal Med, Taipei Branch, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Med, Dept Med Res, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Taipei 10764, Taiwan
[6] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
关键词
hepatitis C virus; viral kinetics; pegylated interferon; interferon; ribavirin;
D O I
10.1159/000105444
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objectives: Early hepatitis C viral ( HCV) kinetics following pegylated interferon-alpha (PEG-IFN) and ribavirin help to assess treatment in the Western world. Whether this functions in Taiwanese patients remains unknown. Studying the early HCV kinetics in Taiwanese patients may clarify this issue. Methods: Six chronic hepatitis C patients were enrolled. A PEG-IFN-alpha dose was administered at week 1, then it was administered weekly with daily ribavirin for 24 weeks. Serum HCV RNA levels were determined frequently during the trial and qualitatively at week 49. Kinetic parameters epsilon ( effectiveness at inhibiting viral production) and delta ( loss rate of infected cells) were estimated from viral loads and alanine aminotransferase ( ALT) kinetics, respectively. Results: All serum HCV RNA levels became undetectable at week 12. The epsilon ranged from 0.4128 to 0.9904 and delta from 0.0019 to 0.1245. The log values of viral load differences between day 7 and 14 ranged from 0.15 to 1.21. Only 1 patient had an abnormal ALT level at week 49. Conclusions: Viral kinetic parameters in Taiwanese patients were similar to those in Western studies. However, the early viral decline pattern and viral negativity rate in Taiwanese patients might be different from Caucasian patients. Further large-scale studies to clarify this issue are ongoing. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [41] Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
    Nattiya Kapol
    Surasit Lochid-amnuay
    Yot Teerawattananon
    BMC Gastroenterology, 16
  • [42] Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection
    Hermos, John A.
    Quach, Lien
    Gagnon, David R.
    Weber, H. Christian
    Altincatal, Arman
    Cho, Kelly
    Lawler, Elizabeth V.
    Grotzinger, Kelly M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (05) : 480 - 488
  • [43] Relationship between Regulatory T Cells and the Combination of Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis Type C
    Akiyama, Motohisa
    Ichikawa, Tatuki
    Miyaaki, Hisamitsu
    Motoyoshi, Yasuhide
    Takeshita, Shigeyuki
    Ozawa, Eisuke
    Miuma, Satoshi
    Shibata, Hidetaka
    Taura, Naota
    Nakao, Kazuhiko
    INTERVIROLOGY, 2010, 53 (03) : 154 - 160
  • [44] Chronic hepatitis C and Crohn's disease:: Nosocomial infection treatment with PEG-interferon plus ribavirin
    Salcedo-Mora, Xamila
    Mate, Jose
    Medina, Jesus
    Chab, Syong J. Nam
    Gisbert, Javier P.
    Moreno-Otero, Ricardo
    DIGESTION, 2006, 73 (04) : 210 - 214
  • [45] Impact of early elevation of serum bilirubin during treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C
    Ishigami, Masatoshi
    Hayashi, Kazuhiko
    Katano, Yoshiaki
    Itoh, Akihiro
    Hirooka, Yoshiki
    Goto, Hidemi
    HEPATOLOGY RESEARCH, 2010, 40 (10) : 963 - 970
  • [46] Pegylated interferon alfa and ribavirin for children with chronic hepatitis C
    Irit Rosen
    Michal Kori
    Orly Eshach Adiv
    Baruch Yerushalmi
    Nataly Zion
    Ron Shaoul
    World Journal of Gastroenterology, 2013, (07) : 1098 - 1103
  • [47] Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
    Kapol, Nattiya
    Lochid-amnuay, Surasit
    Teerawattananon, Yot
    BMC GASTROENTEROLOGY, 2016, 16
  • [48] Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin
    Wu, Chia-Min
    Su, Fu-Hsiung
    Muo, Chih-Hsin
    Huang, Jou-Chen
    Wu, Meei-Maan
    Yeh, Chih-Ching
    VIRUSES-BASEL, 2021, 13 (03):
  • [49] Hepatitis C and treatment with pegylated interferon and ribavirin
    Gotto, J
    Dusheiko, GM
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (10) : 1874 - 1877
  • [50] Pegylated interferon alfa and ribavirin for children with chronic hepatitis C
    Rosen, Irit
    Kori, Michal
    Adiv, Orly Eshach
    Yerushalmi, Baruch
    Zion, Nataly
    Shaoul, Ron
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (07) : 1098 - 1103